Evidence map›Paper›PMID 40222985›Full record

ArticleScientific reports2025

Genome-wide association study of common side effects following COVID-19 booster vaccination in a cohort of corporate employees in Japan.

Yosuke Omae, Seik-Soon Khor, Mihoko Shimada, Yosuke Kawai, Taihei Yamaguchi, Maiko Yagi, Masashi Ebisawa, Junko S Takeuchi, Tetsuya Mizoue, Wataru Sugiura and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yosuke OmaeGenome Medical Science Project, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Seik-Soon KhorGenome Medical Science Project, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Mihoko ShimadaGenome Medical Science Project, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Yosuke KawaiGenome Medical Science Project, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Taihei YamaguchiLife Science Business Office, Corporate Technology Planning Division, Toshiba Corporation, Tokyo, Japan.
Maiko YagiLife Science Business Office, Corporate Technology Planning Division, Toshiba Corporation, Tokyo, Japan.
Masashi EbisawaLife Science Business Office, Corporate Technology Planning Division, Toshiba Corporation, Tokyo, Japan.
Junko S TakeuchiDepartment of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Tetsuya MizoueDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Wataru SugiuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Katsushi TokunagaGenome Medical Science Project, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan. katokunaga@ri.ncgm.go.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individual differences have been observed in side effects after vaccination for COVID-19, and host genetic factors have been suggested as a contributing factor. Here, we conducted a genome-wide association study (GWAS) involving 2,554 Japanese corporate employees who received a third booster dose of BNT162b2/Pfizer or mRNA-1273/Moderna vaccine. Although no genome-wide significant association was found for the presence of adverse symptoms, the GWAS for severity revealed six associated loci. The most significant association was observed between the severity of swelling of lymph nodes and chromosome 2q12 locus, including the IL1RL1, IL18R1, and IL18RAP genes (lead variant: rs76152249; P = 1.46 × 10

Indexed as

COVID-19COVID-19 VaccinesGenome-Wide Association StudyImmunization, SecondaryAdultBNT162 VaccineCohort StudiesFemaleHumansJapanMaleMiddle AgedPolymorphism, Single NucleotideSARS-CoV-2VaccinationBNT162 VaccineCOVID-19 VaccinesCommon side effectsCOVID-19GWASHLAMHC locusVaccination

Identifiers

PMID40222985
PMCPMC11994816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.